PL372091A1 - Ekspresja genów w zmodyfikowanym wirusie krowianki Ankara uzyskana w wyniku zastosowania promotora ATI wirusa ospy krów - Google Patents
Ekspresja genów w zmodyfikowanym wirusie krowianki Ankara uzyskana w wyniku zastosowania promotora ATI wirusa ospy krówInfo
- Publication number
- PL372091A1 PL372091A1 PL03372091A PL37209103A PL372091A1 PL 372091 A1 PL372091 A1 PL 372091A1 PL 03372091 A PL03372091 A PL 03372091A PL 37209103 A PL37209103 A PL 37209103A PL 372091 A1 PL372091 A1 PL 372091A1
- Authority
- PL
- Poland
- Prior art keywords
- modified vaccinia
- gene expression
- virus
- ati promoter
- vaccinia virus
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10344—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/60—Vector systems having a special element relevant for transcription from viruses
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Health & Medical Sciences (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Gastroenterology & Hepatology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200200754 | 2002-05-16 | ||
| DK200201813A DK200201813A (da) | 2002-11-25 | 2002-11-25 | Ekspression af gener i modificeret vaccinia virus ankara ved brug af ATI promotoren fra ko-kopper |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL372091A1 true PL372091A1 (pl) | 2005-07-11 |
Family
ID=29551229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL03372091A PL372091A1 (pl) | 2002-05-16 | 2003-05-14 | Ekspresja genów w zmodyfikowanym wirusie krowianki Ankara uzyskana w wyniku zastosowania promotora ATI wirusa ospy krów |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20060029619A1 (pl) |
| EP (1) | EP1404852B1 (pl) |
| JP (1) | JP2005525821A (pl) |
| KR (1) | KR20040108804A (pl) |
| CN (1) | CN1289682C (pl) |
| AT (1) | ATE313641T1 (pl) |
| AU (1) | AU2003240243B2 (pl) |
| BR (1) | BR0310020A (pl) |
| CA (1) | CA2481783A1 (pl) |
| DE (1) | DE60302848T2 (pl) |
| DK (1) | DK1404852T3 (pl) |
| EA (1) | EA009525B1 (pl) |
| ES (1) | ES2256747T3 (pl) |
| IL (1) | IL164179A0 (pl) |
| MX (1) | MXPA04011034A (pl) |
| NO (1) | NO20045315L (pl) |
| NZ (1) | NZ536500A (pl) |
| PL (1) | PL372091A1 (pl) |
| SI (1) | SI1404852T1 (pl) |
| WO (1) | WO2003097844A1 (pl) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002042480A2 (en) * | 2000-11-23 | 2002-05-30 | Bavarian Nordic A/S | Modified vaccinia ankara virus variant |
| US7501127B2 (en) | 2002-05-16 | 2009-03-10 | Bavarian Nordic A/S | Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara |
| UA85543C2 (ru) * | 2002-09-05 | 2009-02-10 | Бавариан Нордик А/С | Способ культивирования первичных клеток и амплификации вирусов в условиях безсывороточной среды, композиция и ее применение, и способ лечения или вакцинации животных |
| ATE471383T1 (de) | 2003-11-24 | 2010-07-15 | Bavarian Nordic As | Promotoren zur expression in modifiziertem vaccinia virus ankara |
| EP1835031A1 (en) | 2006-03-14 | 2007-09-19 | Paul-Ehrlich-Institut Bundesamt für Sera und Impfstoffe | Use of a recombinant modified vaccinia virus Ankara (MVA) for the treatment of type I hypersensitivity in a living animal including humans |
| WO2008076157A2 (en) * | 2006-09-08 | 2008-06-26 | Duke University | Modified vaccinia ankara virus vaccine |
| US8394385B2 (en) * | 2009-03-13 | 2013-03-12 | Bavarian Nordic A/S | Optimized early-late promoter combined with repeated vaccination favors cytotoxic T cell response against recombinant antigen in MVA vaccines |
| SG178909A1 (en) | 2009-10-08 | 2012-04-27 | Bavarian Nordic As | Generation of a broad t-cell response in humans against hiv |
| WO2013189611A1 (en) | 2012-06-22 | 2013-12-27 | Bavarian Nordic A/S | Poxviral vectors for low antibody response after a first priming immunization |
| FR3042121A1 (fr) | 2015-10-08 | 2017-04-14 | Jean-Marc Limacher | Composition anti-tumorale |
| CN109172818B (zh) * | 2018-08-02 | 2021-10-22 | 浙江康佰裕生物科技有限公司 | 一种蛋白牛痘疫苗及其效力检测方法 |
| KR102920141B1 (ko) | 2019-03-14 | 2026-01-29 | 고에키자이단호진 도쿄도 이가쿠 소고겐큐쇼 | 뎅기 바이러스 백신 |
| FR3160186A1 (fr) | 2024-03-13 | 2025-09-19 | Odimma Therapeutics | Vecteur non-viral pour transcription augmentee |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0795956B2 (ja) * | 1986-09-22 | 1995-10-18 | 京都大学長 | ポックスウイルス由来発現制御領域 |
| JPH01218590A (ja) * | 1988-02-29 | 1989-08-31 | Toa Nenryo Kogyo Kk | 組換ワクチニアウイルスを用いたリンダペスト（牛疫）ウイルスワクチン |
| AU625584B2 (en) * | 1989-03-08 | 1992-07-16 | Health Research Inc. | Recombinant poxvirus host selection system |
| US5225336A (en) * | 1989-03-08 | 1993-07-06 | Health Research Incorporated | Recombinant poxvirus host range selection system |
| US5452364A (en) * | 1993-12-07 | 1995-09-19 | Bonham; Douglas M. | System and method for monitoring wildlife |
| UA68327C2 (en) * | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
| US6869793B2 (en) * | 1996-09-24 | 2005-03-22 | Bavarian Nordic Research Institute | Recombinant MVA virus expressing dengue virus antigens, and the use thereof in vaccines |
| ATE412762T1 (de) * | 1999-05-28 | 2008-11-15 | Helmholtz Zentrum Muenchen | Vektor zur integration von heterologen sequenzen in poxvirusgenomen |
| WO2002042480A2 (en) * | 2000-11-23 | 2002-05-30 | Bavarian Nordic A/S | Modified vaccinia ankara virus variant |
-
2003
- 2003-05-14 BR BR0310020-0A patent/BR0310020A/pt not_active IP Right Cessation
- 2003-05-14 AT AT03732369T patent/ATE313641T1/de not_active IP Right Cessation
- 2003-05-14 NZ NZ536500A patent/NZ536500A/en not_active IP Right Cessation
- 2003-05-14 CN CNB038106523A patent/CN1289682C/zh not_active Expired - Fee Related
- 2003-05-14 US US10/514,922 patent/US20060029619A1/en not_active Abandoned
- 2003-05-14 IL IL16417903A patent/IL164179A0/xx not_active IP Right Cessation
- 2003-05-14 SI SI200330175T patent/SI1404852T1/sl unknown
- 2003-05-14 KR KR10-2004-7018205A patent/KR20040108804A/ko not_active Ceased
- 2003-05-14 MX MXPA04011034A patent/MXPA04011034A/es active IP Right Grant
- 2003-05-14 JP JP2004506499A patent/JP2005525821A/ja active Pending
- 2003-05-14 WO PCT/EP2003/005046 patent/WO2003097844A1/en not_active Ceased
- 2003-05-14 EA EA200401505A patent/EA009525B1/ru not_active IP Right Cessation
- 2003-05-14 ES ES03732369T patent/ES2256747T3/es not_active Expired - Lifetime
- 2003-05-14 PL PL03372091A patent/PL372091A1/pl unknown
- 2003-05-14 AU AU2003240243A patent/AU2003240243B2/en not_active Ceased
- 2003-05-14 CA CA002481783A patent/CA2481783A1/en not_active Abandoned
- 2003-05-14 DE DE60302848T patent/DE60302848T2/de not_active Expired - Lifetime
- 2003-05-14 EP EP03732369A patent/EP1404852B1/en not_active Expired - Lifetime
- 2003-05-14 DK DK03732369T patent/DK1404852T3/da active
-
2004
- 2004-12-03 NO NO20045315A patent/NO20045315L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20040108804A (ko) | 2004-12-24 |
| DE60302848T2 (de) | 2006-08-31 |
| DE60302848D1 (de) | 2006-01-26 |
| WO2003097844A1 (en) | 2003-11-27 |
| EP1404852B1 (en) | 2005-12-21 |
| NZ536500A (en) | 2008-01-31 |
| MXPA04011034A (es) | 2005-02-14 |
| HK1076835A1 (zh) | 2006-01-27 |
| NO20045315L (no) | 2004-12-03 |
| AU2003240243B2 (en) | 2009-01-22 |
| BR0310020A (pt) | 2005-02-15 |
| AU2003240243A1 (en) | 2003-12-02 |
| EA200401505A1 (ru) | 2005-04-28 |
| EP1404852A1 (en) | 2004-04-07 |
| IL164179A0 (en) | 2005-12-18 |
| ATE313641T1 (de) | 2006-01-15 |
| SI1404852T1 (sl) | 2006-04-30 |
| US20060029619A1 (en) | 2006-02-09 |
| DK1404852T3 (da) | 2006-05-08 |
| CA2481783A1 (en) | 2003-11-27 |
| JP2005525821A (ja) | 2005-09-02 |
| EA009525B1 (ru) | 2008-02-28 |
| CN1289682C (zh) | 2006-12-13 |
| ES2256747T3 (es) | 2006-07-16 |
| CN1653181A (zh) | 2005-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA85379C2 (ru) | Рекомбинантный поксвирус, содержащий как минимум два ati промотора коровьей оспы | |
| PL372091A1 (pl) | Ekspresja genów w zmodyfikowanym wirusie krowianki Ankara uzyskana w wyniku zastosowania promotora ATI wirusa ospy krów | |
| NO20045480L (no) | Intergeniske regioner som innskuddsseter i genomet til vacciniavirus ankara(MVA) | |
| WO2003047617A3 (en) | Vaccine | |
| DK1425404T3 (da) | Vaccinia-MVA-E3L-mutanter og anvendelse deraf | |
| DK1881845T3 (da) | Nipah-virusvacciner | |
| AU2003219057A8 (en) | Recombinant drug-sensitive vaccinia virus as smallpox vaccine | |
| ATE377088T1 (de) | Promotoren zur expression in modifiziertem vaccinia virus ankara | |
| WO2002086059A3 (en) | Recombinant vaccinia viral vectors | |
| ATE504653T1 (de) | Vaccinia virus wirtspektrum gene zur erhöhung des titers von avipoxviren | |
| AU2003249059A1 (en) | Use of vaccinia virus deleted for the e3l gene as a vaccine vector | |
| WO2008030260A3 (en) | Treatment of variola viral infections using a tissue factor inhibitor | |
| DE50312368D1 (de) | Rekombinante mva-stamme als potentielle impfstoffe gegen p. falciparum -malaria | |
| DE60209345D1 (de) | Leporipox-basierende vektorvakzine | |
| WO2002046214A3 (en) | Immunomodulatory protein derived from the yaba monkey tumor virus | |
| NO942075L (no) | Rekombinante virus omfattende kunstig proteolytisk spaltingssete | |
| BR0316553A (pt) | Poxvìrus recombinante que compreende pelo menos dois promotores ati de varìola bovina | |
| SI1420822T1 (sl) | Modificiran virus vakcinije Ankara za vakcinacijonovorojenčkov |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DISC | Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications) |